| 5-HT | Serotonin |
| 5-HT2A | Serotonin 5-HT2A receptor |
| 5-HT2C | Serotonin 5-HT2C receptor |
| 5-HT3 | Serotonin 5-HT3 receptor |
| ACR | American College of Rheumatology |
| ANXA1 | Annexin A1 |
| AP-1 | Activator protein 1 |
| ASIC | Acid-sensing ion channel |
| AXIN1 | Axis inhibition protein 1 |
| BBB | Blood–brain barrier |
| BDNF | Brain-derived neurotrophic factor |
| C1QC | Complement C1q C chain |
| C4A | Complement component 4 |
| CB1 | Cannabinoid receptor 1 |
| CB2 | Cannabinoid receptor 2 |
| CCL13 | Chemokine (C-C motif) ligand 13 |
| CCL2 | Chemokine (C-C motif) ligand 2 |
| CCL4 | Chemokine (C-C motif) ligand 4 |
| CD163 | Cluster of differentiation 163 |
| CNS | Central nervous system |
| CoQ10 | Coenzyme Q10 |
| CRP | C-reactive protein |
| CSF | Cerebrospinal fluid |
| CSU | Chronic spontaneous urticaria |
| CX3CL1 | Chemokine (C-X3-C motif) ligand 1 |
| D2 | Dopamine D2 receptor |
| DII | Dietary Inflammatory Index |
| DNA | Deoxyribonucleic acid |
| DRG | Dorsal root ganglia |
| ELISA | Enzyme-linked immunosorbent assay |
| ERK | Extracellular signal-regulated kinase |
| EULAR | European Alliance of Associations for Rheumatology |
| FBD | Functional bowel disorder |
| FMT | Fecal microbiota transplantation |
| FODMAP | Fermentable oligo-, di-, and mono-saccharides and polyols |
| GDNF | Glial-cell-line-derived neurotrophic factor |
| JNK | c-Jun N-terminal kinase |
| IBS | Irritable bowel syndrome |
| IGF-1 | Insulin-like growth factor 1 |
| IL-10 | Interleukin 10 |
| IL-13 | Interleukin 13 |
| IL-17 | Interleukin 17 |
| IL-1β | Interleukin 1 beta |
| IL-21 | Interleukin 21 |
| IL-22 | Interleukin 22 |
| IL-37 | Interleukin 37 |
| IL-4 | Interleukin 4 |
| IL-6 | Interleukin 6 |
| IL-8 | Interleukin 8 |
| IGUBAC-Diet® | Inflammatory gut–brain axis control diet |
| MMP-3 | Matrix metalloproteinase-3 |
| MOR | μ-opioid receptor |
| NA | Noradrenaline |
| NF-κB | Nuclear factor kappa-light-chain-enhancer of activated B cells |
| NMDA | N-methyl-D-aspartate |
| NPY | Neuropeptide Y |
| NRI | Selective noradrenaline reuptake inhibitor |
| NSAID | Non-steroidal anti-inflammatory drug |
| p38 MAPK | p38 mitogen-activated protein kinase |
| PGAM1 | Phosphoglycerate mutase 1 |
| RAGE | Receptor for advanced glycation end products |
| RCT | Randomized controlled trial |
| RLS | Restless leg syndrome |
| RNA | Ribonucleic acid |
| RT-qPCR | Reverse transcription-quantitative polymerase chain reaction |
| S100 | S100 protein |
| S100A8 | S100 calcium-binding protein A8 |
| S100A9 | S100 calcium-binding protein A9 |
| SERPINA1 | Serpin family A member 1 |
| SIRT2 | NAD-dependent deacetylase sirtuin 2 |
| SNRI | Serotonin-noradrenaline reuptake inhibitor |
| SP | Substance P |
| SS | Symptom Severity |
| SSRI | Selective serotonin reuptake inhibitor |
| TCA | Tricyclic antidepressant |
| TLR4 | Toll-like receptor 4 |
| TNF-α | Tumor necrosis factor alpha |
| TRPV | Transient receptor potential vanilloid |
| VCAM | Vascular cell adhesion molecule |
| VGCC | Voltage-gated calcium channel |
| WPI | Widespread Pain Index |